Short answer
Harmony Biosciences Holdings, Inc. (HRMY) filed an 8-K current report with the SEC on April 2, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Peter Anastasiou appointed COO, with $600,000 salary, 55% target bonus, and $3.7 million option award.
Harmony Biosciences Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Peter Anastasiou appointed COO, with $600,000 salary, 55% target bonus, and $3.7 million option award
- Anastasiou’s move from director to COO consolidates operational leadership but reduces board membership by one
- Troy Ignelzi appointed independent Class III director and joins Audit and Compensation Committees effective May 14, 2026
- Antonio Gracias will not seek re-election, creating another Class III board transition at the 2026 annual meeting
- COO severance includes 12 months’ salary and healthcare, with accelerated option vesting following a change in control
Item 7.01 · Regulation FD Disclosure
- Item 7.01 contains only incorporation-by-reference language
- No substantive investor information or market-moving disclosure in the provided text
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Harmony Biosciences Holdings, Inc. 8-K filings
Get the next HRMY 8-K as it lands
Follow HRMY for push alerts, or ask the research agent what this filing means.